home

Soon-Shiong's NantKwest is spending more on stock buybacks than R&D

CommentsNantKwest2015-11-14 00:07 Read   1203

NantKwest ($NK), an oncology biotech in Patrick Soon-Shiong's constellation of companies, made headlines over the summer when it pulled off a $200 million IPO that valued it at more than $2.5 billion. But the company's share value has slipped by nearly a third in the ensuing months, and instead of pouring money into developing its self-described breakthrough medicines, management has taken the uncommon tack of laying out $50 million to buy back stock.

GSK Announces Positive Results From Phase III BLISS-SC Study of Benlysta(R) (Belimumab) Administered Subcutaneously In Patients With Systemic Lupus Erythematosus (SLE)

TrendGSK,Belimumab,SLE2015-11-12 14:23 Read   1233

GSK announced results from the BLISS-SC Phase III pivotal study in patients with active, autoantibody-positive systemic lupus erythematosus (SLE). These results, which are being presented at the American College of Rheumatology/Association for Rheumatology Health Professionals Annual Meeting, showed that Benlysta® (belimumab) 200mg administered weekly via subcutaneous injection plus standard of care (SoC), showed significantly greater reductions in disease activity compared to placebo plus SoC.

Amgen Presents Detailed Results From Phase 3 Study Demonstrating Clinical Equivalence Of Biosimilar Candidate ABP 501 With Adalimumab

TrendAmgen2015-11-11 13:44 Read   463

Amgen today presented detailed findings from a head-to-head Phase 3 study comparing the safety, efficacy and immunogenicity of biosimilar candidate ABP 501 with adalimumab in patients with moderate-to-severe rheumatoid arthritis.

Teva Announces Breakthrough Therapy Designation for SD-809 Granted by FDA for the Treatment of Tardive Dyskinesia

TrendTeva2015-11-10 14:11 Read   404

Teva Pharmaceutical Industries Ltd. (NYSE and TASE:TEVA) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation status to SD-809 (deutetrabenazine) for the treatment of patients with moderate to severe tardive dyskinesia, a hyperkinetic movement disorder affecting about 500,000 people in the United States

Lilly and Incyte Announce Patients Treated with Baricitinib Demonstrated Significant Improvement in Signs and Symptoms of Rheumatoid Arthritis Compared with Methotrexate

TrendLilly and Incyte2015-11-09 15:28 Read   1066

Improvements compared to methotrexate were seen for baricitinib alone or in combination with methotrexate as early as week 1 for all components of the ACR response (swollen and tender joint counts, pain, patient and physician global assessment of disease activity and physical function). These improvements were maintained at weeks 24 and 52

Samsung Bioepis' SB4 and SB2 Investigational Biosimilar Candidates Sustain Comparable Safety Profiles in One-Year Phase 3 Clinical Studies

TrendSamsung Bioepis2015-11-09 09:54 Read   829

Positive one-year results show SB4 etanercept and SB2 infliximab investigational biosimilar candidates sustained comparable safety profiles observed in previously announced primary results

Allergan Outlines Open Science Model And Highlights Key Development Programs At R&D Day

TrendAllergan2015-11-06 16:33 Read   280

Open Science Strategy Seeks to Deliver Innovation from Healthcare Ecosystem . Company's Pipeline Features More Than 70 Mid-to-Late Stage Development Programs with Game-Changing Opportunities Across Seven Therapeutic Categories .Clinical Data and Regulatory Milestone Updates Featured in R&D Day .Allergan Builds on Open Science Strategy with Acquisition of Earfold, and Licensing of Mimetogen's Tavilermide.

Isis Pharmaceuticals and Akcea Therapeutics Announce Start of Phase 3 Study of Volanesorsen in Patients with Familial Partial Lipodystrophy

R&DIsis2015-11-06 14:37 Read   594

Trial marks second study for volanesorsen in a rare, genetic lipid disorder

Allergan delivers 'decent' Q3 sales growth, with price hikes driving half of it

CommentsAllergan2015-11-05 14:07 Read   478

All eyes are on Allergan's ($AGN) friendly deal talks with Pfizer, which is anxious to scoop up an acquisition and complete a tax inversion. But with the Irish drugmaker's execs mum on the possible combo Wednesday, the conversation turned to new product launches, drug pricing, and Q3 financials that looked "pretty good".

Merck KGaA, Darmstadt, Germany, and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer

R&DPfizer 2015-11-05 13:40 Read   781

Trial marks second Phase III study of avelumab in non-small cell lung cancer (NSCLC) initiated by Merck KGaA, Darmstadt, Germany, and Pfizer in just over six months.

Good thing Bayer's in Germany, CEO says. U.S. business culture is too impatient

CommentsFT story2015-11-04 11:15 Read   272

Bayer CEO Marijn Dekkers knows what it is to push it to the limit. But he also knows that too much pushing can take its toll.

Zoetis to Acquire PHARMAQ, the Global Leader in Vaccines and Innovation for Health Products in Aquaculture

TrendZoetis2015-11-04 10:34 Read   352

Zoetis announced an agreement to purchase PHARMAQ, the global leader in vaccines and innovation for health products in aquaculture, for a price of $765 million on a debt-free basis. Acquiring PHARMAQ strengthens Zoetis' core livestock business, giving the company a market-leading presence in the fastest growing segment of the animal health industry.